Pasar al contenido principal

ESTRATEGIAS FARMACOLOGICAS DE PREVENCION DEL CANCER DE MAMA MEDIANTE MODIFICACION DE LA INVOLUCION POSTLACTANCIA

SAF2017-88854-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Identification of genetic and molecular determinants associated with cardiotoxicity by anthracyclines and taxanes according to age

  • Gómez-Vecino, Aurora
  • Corchado Cobos, Roberto
  • Blanco-Gómez, Adrián
  • Prieto, Carlos
  • Patino-Alonso, María Carmen
  • Galindo, P.
  • Fraile, Susana
  • Rodrigues Teixeira, Telmo
  • García-Macías, Carmen
  • Galvis-Jiménez, Julie Milena
  • García Sánchez, Asunción
  • Isidoro-García, María
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • García-Sancha, Natalia
  • Holgado-Madruga, Marina
  • Sánchez-Fernández, Pedro Luis
  • Pérez-Losada, J.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: Cardiotoxicity due to anthracyclines (CDA) is a very common problem in cancer patients, with great repercussion on their quality of life, which limits chemotherapy treatment and has consequences in the final prognosis of the oncologic disease itself. The susceptibility and degree of cardiotoxicity by anthracyclines is very heterogeneous among patients, and who will suffer this complication is unknown. CDA is a complex trait, thus follows a model of quantitative genetics, whose polygenic component is mostly unidentified. In addition, as a complex trait, CDA heterogeneity is explained by the variability among subphenotypes that would participate in its pathogenesis. Thus, anthracyclines exert their toxicity through DNA damage, so that among these subphenotypes would be the molecular pathways involved in the response to it, and a series of signaling pathways that promote and others that protect from that heart damage anthracyclines have a pro-genotoxicity effect. Differences in these pathways with the genetic variants linked with them could contribute to different susceptibility to CDA among individuals., [Material and Methods]: we identified the genetic and molecular determinants of cardiotoxicity in a simplified model of controlled genetic and phenotypic heterogeneity, generated by a backcross of two mouse strains of divergent phenotypic behavior, FVB and C57BL/6. We evaluated cardiac damage at histopathological level and also quantified different subphenotypes such as signaling pathways associated with cardiac damage and protection, genotoxicity pathways, TGFβ levels, telomere length, and expression of miRNAs in the myocardium., [Results]: We quantified anthracycline cardiotoxicity in a heterogeneous cohort of mice with breast cancer generated by a backcross. Cardiotoxicity was higher in old mice, was higher in the combined treatment with taxanes, was higher in the subendocardial zone and was influenced by the genetic background. We have identified multiple QTL associated with CDA in these different conditions studied. Differences in the grade of anthracycline cardiotoxicity at the histopathological level were accompanied by differences in the molecular levels in the myocardium of different molecular components of the pathways of response to damage at DNA, signaling pathways, miRNAs and telomere length. QTLs associated with these subphenotypes help to define CDA variability. Lastly, we have also defined CDA by multivariate models., [Conclusion]: The identification of genetic and molecular factors responsible for the increased risk of CDA will contribute to a better understanding of their pathophysiology, which could lead to new approaches to predict, prevent and treat this serious complication of chemotherapy., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), “Proyectos Integrados IBSAL 2015” (IBY15/00003), the Sandra Ibarra Foundation “de Solidaridad Frente al Cáncer” Foundation and “We can be heroes” Foundation., Peer reviewed